LGND Ligand Pharmaceuticals Incorporated

NASDAQ
$296.94

Ligand Pharmaceuticals Incorporated (LGND) Institutional Ownership

What the institutions did with LGND last quarter, from their 13F filings. Counting managers rather than shares is the point: a single index fund adding to a position tells you far less than four hundred separate managers all deciding to. Positions as reported for the quarter ended September 30, 2026.

Managers compared
3
filed both this quarter and last
Managers holding
3
+0 on the quarter
Buyers
1
0 opened new
Sellers
2
0 sold out entirely
Buyer share
33.3%
of managers who traded it
Breadth
-33.3
net buyers, as a share of those trading

Only 3 managers reported a position this quarter, so the percentages above describe a very small sample.

Every manager below opens. Subscribers can see any firm's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.

Sign in or subscribe

Largest holders

Manager Shares % of reported
ARGENT CAPITAL MANAGEMENT LLC 3.5K 90.4%
Versant Capital Management, Inc 265 6.8%
MassMutual Private Wealth & Trust, FSB 112 2.9%

Largest changes

Manager Action Previous Current Change
ARGENT CAPITAL MANAGEMENT LLC Reduced 3.8K 3.5K -263
MassMutual Private Wealth & Trust, FSB Reduced 117 112 -5
Versant Capital Management, Inc Increased 261 265 +4

13F filings are due 45 days after quarter end and cover long positions in U.S.-listed equities only, so this is a lagged and partial picture: shorts, bonds and foreign listings never appear. Options positions are excluded here rather than folded into the share counts. Political ownership is coming.